أعرض في EDS

Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck

التفاصيل البيبلوغرافية
العنوان: Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck
المؤلفون: Sarah A. Taylor, Danika Lew, Roy E. Smith, G. I. Rodriguez, John F. Ensley, David E. Schuller
المصدر: Investigational New Drugs. 14:403-407
بيانات النشر: Springer Science and Business Media LLC, 1996.
سنة النشر: 1996
مصطلحات موضوعية: Adult, Male, Oncology, medicine.medical_specialty, medicine.medical_treatment, Antineoplastic Agents, Drug Administration Schedule, Lethargy, Internal medicine, medicine, Humans, Pharmacology (medical), Prior Radiation Therapy, Aged, Aged, 80 and over, Pharmacology, Chemotherapy, business.industry, Head and neck cancer, Middle Aged, medicine.disease, Confidence interval, Radiation therapy, Epidermoid carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Camptothecin, Female, Topotecan, business, medicine.drug
الوصف: Twenty-nine patients with persistent, recurrent and/or metastatic squamous cell carcinoma of the head and neck were treated daily for five days at three-week intervals with topotecan 1.5 mg/m2. Four patients received prior chemotherapy, 23 prior surgery and 29 prior radiation therapy. Of the 29 eligible patients, 8 patients were not evaluable for response and were assumed to be non-responders. Of the remaining 21 evaluable patients, there were zero responses (0%, 95% confidence interval [0,.12]). The most common toxicities were myelosuppression, dyspnea and malaise/fatigue/lethargy. Topotecan has limited activity in advanced head and neck cancer with this dose and schedule.
تدمد: 1573-0646
0167-6997
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abf5f27e4d14b2bd21fc0254c6228c8e
https://doi.org/10.1007/bf00180818
حقوق: CLOSED
رقم الأكسشن: edsair.doi.dedup.....abf5f27e4d14b2bd21fc0254c6228c8e
قاعدة البيانات: OpenAIRE
الوصف
تدمد:15730646
01676997